色瑞替尼ZYKADIA（ceritinib）

Ceritinib ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastases who have progressed on or are intolerant to crizotinib for non-small cell lung cancer (NSCLC).

[Specifications]
150 mg;

[Dosage and Administration]
The recommended dose of Ceritinib ZYKADIA is 750 mg, once a day, orally until disease progression or unacceptable toxicity, and ZYKADIA is administered on an empty stomach (i.e., not within 2 hours of a meal). As with crizotinib, grapefruit juice should not be consumed during medication.

[Adverse Reactions]
The most common adverse reactions (incidence of at least 25%) are diarrhea, nausea, elevated transaminases, vomiting, abdominal pain, fatigue, loss of appetite, and constipation.

【Warnings and Precautions】
⑴ Severe and persistent gastrointestinal toxicity: Adjust the dose due to diarrhea, nausea, vomiting or abdominal pain in 38% of patients. If there is no response to antiemetic or antidiarrheal drugs, do not administer and then reduce the dose of ZYKADIA.
⑵ Hepatotoxicity: ZYKADIA may cause hepatotoxicity. Monitor liver laboratory tests at least monthly. Do not administer and then reduce the dose, or permanently discontinue ZYKADIA.
⑶ Interstitial lung disease (ILD)/pneumonitis: Occurred in 4% of patients. Permanently discontinue ZYKADIA in patients diagnosed with treatment-related ILD/pneumonitis.
⑷ QT interval prolongation: ZYKADIA may cause QTc interval prolongation. Monitor ECG and electrolytes in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or patients taking drugs known to prolong the QTc interval. Do not administer or reduce the dose, or permanently discontinue ZYKADIA.
⑸ Hyperglycemia: ZYKADIA may cause hyperglycemia. Monitor blood sugar and take anti-hyperglycemic drugs. If blood sugar cannot be controlled, do not take the drug or reduce the dose, or permanently discontinue ZYKADIA.
⑹ Bradycardia: ZYKADIA may cause bradycardia. Monitor heart rate and blood pressure regularly. If bradycardia cannot be controlled, do not take the drug or reduce the dose, or permanently discontinue ZYKADIA.
⑺ Embryo-fetal toxicity: ZYKADIA may cause fetal harm. Advise women of reproductive potential to take contraceptive measures during medication.

[Contraindications]
Severe allergies to this product or the inactive ingredients of the drug are prohibited.

Note: If the drug has a new packaging, the new packaging shall prevail. The above information comes from the Internet or is translated by student volunteers from higher medical colleges (please help correct if there are any errors or omissions). It is only for internal discussion among medical staff and is not used as any basis for medication. For specific medication instructions, please consult the attending physician.